A director at Becton Dickinson & Co sold 1,715 shares at 232.810USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Rush Street Interactive Announces First Quarter 2024 Results and Raises Full Year Guidance - First Quarter Revenue of $217 Million, up 34% Year-over-Year -- First Quarter Net Loss of $2 Million -- Strong Operating Momentum Drives First Quarter Adjusted EBITDA of $17 Million -- Raising Full Year 2024 Adjusted EBITDA Guidance 38% at the Midpoint with a Revised Range of Between $50 and $60 Million - CHICAGO, May 01, 2024 (GLOBE NEWSWIRE) -- Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”), a leading online casino and sports betting company in the United States and the rest of the Americas,...
Two Directors at Kimberly Clark Corp sold/sold after exercising options 14,168 shares at between 135.240USD and 135.527USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with. “In rare disease, corporate responsibility means pushing for progress and change t...
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025 WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 stu...
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta (OI). The pivotal Phase 3 portion of the Orbit study has randomized 158 patients ages 5 to 25 years, and the Cosmic study has completed enroll...
Libro Credit Union Selects nCino to Empower Employees and Positively Impact Ontario Community Top Ontario-based credit union to replace legacy platforms with nCino’s single platform for a more seamless user experience and streamlined lending operations TORONTO, April 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that has selected to empower its employees through data, achieve faster time to value and create a smoother experience for customers. Libro is one of Ontario’s largest credit unions, servin...
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivity to September 2030: Pediatric Narcolepsy sNDA PDUFA Date of June 21, 2024; PW...
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024. The live and replayed webcast of the call will be available through ...
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain ...
Shifting Exposure From Growth to Value Note: This is an abbreviated report (no detailed Sector comments or Russell grids). We will return to our normal report structure next week. While the market remains in consolidation/pullback mode and we are not out of the woods, it is possible that further downside is limited from here on the S&P 500. Since late-February, we have discussed important gap support from 2/22/24 at 4983-5050 on the S&P 500, and that as long as the S&P 500 is above 4983 that b...
SAN FRANCISCO--(BUSINESS WIRE)-- (NYSE: RAMP) today released a new study, “Data Collaboration Fuels Revenue Growth,” evaluating how business leaders in retail, consumer packaged goods, financial services, and travel and hospitality are using data collaboration to enable a wide range of revenue-driving use cases across their organizations and between ecosystem partners. The LiveRamp-commissioned study, conducted by Forrester Consulting, reveals that 93% of respondents agree that improved data collaboration is critical to driving improvements in customer loyalty, data quality, regulatory compli...
Together Selects nCino to Revolutionise its Lending Business U.K. property lender to leverage nCino’s cloud-based platform across core services LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that , one of the UK’s leading property lenders, has selected to revolutionise and future-proof its business. Together provides finance to people and businesses through a “common-sense approach” to lending and judging each application on its individual merit rather than adopting an automated approac...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan...
Broadcast Legend Mike Francesa Renews Exclusive Partnership With BetRivers New York City Icon and Radio Hall of Famer to Deliver Premium Content and Betting Insights to BetRivers Sports Fans CHICAGO, April 17, 2024 (GLOBE NEWSWIRE) -- Rush Street Interactive, Inc. (NYSE: RSI) ("RSI"), a leading US-based betting and gaming company, proudly announces the renewal of its exclusive multi-year agreement with none other than New York sports broadcasting legend, Mike Francesa. The renewal solidifies Francesa's ongoing commitment to BetRivers. "I'm thrilled to continue my partnership with BetR...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.